Real-world comparative outcomes of integrase inhibitor-based first-line ART

被引：0
|
作者：
Marshall, N. [1 ]
Swaden, L. [1 ]
Burns, F. [1 ]
Smith, C. [2 ]
Arenas, A. [3 ]
Taylor, C. [3 ]
Simmons, K. [4 ]
Amlani, A. [4 ]
King, J. [5 ]
Kegg, S. [5 ]
Reeves, I. [6 ]
Denham, A. [7 ]
Latimer, J. [7 ]
Doctor, J. [8 ]
Larbalestier, N. [8 ]
Simons, R. [8 ]
Farooq, H. [9 ]
Ustianowski, A. [9 ]
Jagitsingh, G. [10 ]
Friday, D. [10 ]
Brook, G. [10 ]
Riddles, C. [10 ]
Mallon, P. [11 ]
Macken, A. [11 ]
Tiango, W. [11 ]
Leen, C. [12 ]
Morris, S. [12 ]
Cairns, A. [12 ]
Page, M. [13 ]
Taylor, S. [13 ]
Barber, T. [14 ]
Stegmann, K. [14 ]
Mackie, N. [15 ]
机构：
[1] Royal Free London NHS Fdn Trust, London, England
[2] UCL, London, England
[3] Kings Coll Hosp NHS Fdn Trust, London, England
[4] Royal Sussex Cty Hosp, Brighton, E Sussex, England
[5] Lewisham & Greenwich NHS Trust, London, England
[6] Homerton Univ Hosp, London, England
[7] Southmead Hosp, Bristol, Avon, England
[8] Guys & St Thomas NHS Fdn Trust, London, England
[9] North Manchester Gen Hosp, Manchester, Lancs, England
[10] London Northwest Healthcare NHS Trust, Harrow, Middx, England
[11] Mater Misericordiae Univ Hosp, Dublin, Ireland
[12] Western Gen Hosp, Edinburgh, Midlothian, Scotland
[13] Heart England NHS Fdn Trust, Birmingham, W Midlands, England
[14] Chelsea & Westminster Hosp, London, England
[15] Imperial Coll Healthcare NHS Trust, London, England
来源：
HIV MEDICINE | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P15
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] Adverse outcomes of first-line integrase inhibitor-based single-tablet antiretroviral regimens in the Spanish VACH cohort
    Teira, R.
    Deig, E.
    Puig, T.
    Galindo, P.
    Merino, L.
    Estrada, V.
    Ribera, E.
    Sepulveda, M.
    Garcia, J.
    Montero, M.
    Munoz-Sanchez, P.
    Peraire, J.
    Castano, M.
    Espinosa, N.
    Martinez, E.
    Tellez, F.
    de la Fuente, B.
    Terron, A.
    Lozano, F.
    Roca, B.
    Munoz-Sanz, A.
    Geijo, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [2] Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment
    Pyngottu, Ashima
    Scherrer, Alexandra U.
    Kouyos, Roger
    Huber, Michael
    Hirsch, Hans
    Perreau, Matthieu
    Yerly, Sabine
    Calmy, Alexandra
    Cavassini, Matthias
    Stoeckle, Marcel
    Furrer, Hansjakob
    Vernazza, Pietro
    Bernasconi, Enos
    Guenthard, Huldrych F.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E2134 - E2141
  • [3] Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study
    Duan, Yichun
    Li, Jielang
    Zhou, Shuang
    Bi, Feng
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [4] Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.
    Monberg, Matthew J.
    Hall, Jennifer P.
    Moon, Rebecca
    Higson, Olivia
    McLaurin, Kimmie
    Dalvi, Tapashi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Frequency and reasons for switching integrase inhibitor-based ART
    Petersen, C.
    Alagaratnam, J.
    Wood, M.
    Ramzan, F.
    Foster, C.
    Fidler, S.
    Winston, A.
    HIV MEDICINE, 2018, 19 : S11 - S11
  • [6] Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results
    Nathan, Paul
    Venugopal, Balaji
    Ali, Jamshed
    Allison, Jennifer
    Ceruso, Mariangela
    Charnley, Natalie
    Griffiths, Richard
    Michael, Agnieszka
    Moore, Kathryn
    Perrot, Valerie
    Prendergast, Aine
    Sharma, Anand
    Szabados, Bernadett
    Larkin, James
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [7] First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
    Moliner, Laura
    Zellweger, Nuria
    Schmid, Sabine
    Bertschinger, Martina
    Waibel, Christine
    Cerciello, Ferdinando
    Froesch, Patrizia
    Mark, Michael
    Bettini, Adrienne
    Blum, Veronika
    Holer, Lisa
    Hayoz, Stefanie
    Fruh, Martin
    Ahmed, Samreen
    Haeuptle, Pirmin
    Bhagani, Shradha
    Steele, Nicola
    Gray, Hannah-Leigh
    Robinson, Stephen D.
    Davidson, Michael
    Cox, Samantha
    Khalid, Taha
    Geldart, Tom R.
    Nolan, Luke
    Scott, Deborah C.
    Hennah, Lindsay
    Newsom-Davis, Tom
    Rathbone, Emma
    Handforth, Catherine
    Denton, Arshi
    Merchant, Shairoz
    Blackhall, Fiona
    Mauti, Laetitia A.
    Califano, Raffaele
    Rothschild, Sacha I.
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (01):
  • [8] First-Line Treatment Outcomes of CML Patients in a Real-World Data Setting in Lebanon
    Nasr, Fadi
    Yehia, Intissar
    El Khoury, Reem
    Diab, Saada
    Al Ghoche, Ahmad
    Nasr, Lewis
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S332 - S333
  • [9] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Timothy J. Brown
    Ronac Mamtani
    Phyllis A. Gimotty
    Thomas B. Karasic
    Yu-Xiao Yang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2345 - 2354
  • [10] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Brown, Timothy J.
    Mamtani, Ronac
    Gimotty, Phyllis A.
    Karasic, Thomas B.
    Yang, Yu-Xiao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2345 - 2354
12345